Bringing In The Catalyst For Positive Change
MAY 13, 2020
This time we invited Dr. Joan (Huaqiong) Shen, M.D., Ph.D., CEO at I-Mab Biopharma. During another webinar Dr. Shen joined one week before, she explained that ‘The flow of knowledge and expertise across geographical, cultural, social, and political boundaries may be the answer to finding solutions to test, treat, and manage patients’.
We felt honored having Dr. Shen this time and learning more about her experience, views, and insights regarding the global effort of fighting against COVID-19, along with the clinical trial progress worldwide.
Invited guests:
Ms. Echo Hindle-Yang, President & CEO, moderated this discussion.
About I-Mab Biopharma:
I-Mab, a clinical stage biopharmaceutical company, engages in the discovery, development, and commercialization of novel or highly differentiated biologics to treat diseases with unmet medical needs, primarily cancers and autoimmune disorders worldwide. It is developing TJ202, a CD38 antibody in Phase III clinical trials to treat multiple myeloma and autoimmune diseases; TJ101, a long-acting human growth hormone that is in Phase II clinical trials to treat pediatric growth hormone deficiency; and TJ301, a IL-6 blocker in Phase II clinical trials for the treatment of ulcerative colitis and other autoimmune diseases. The company's product candidates in Phase I clinical trials include Enoblituzumab, a humanized B7-H3 antibody to treat immuno-oncology; TJ107, a long-acting recombinant human IL-7 to treat cancer treatment-related lymphopenia and cancer immunotherapy; TJC4, a CD47 monoclonal antibody with RBC-sparing differentiation; TJD5, a CD73 antibody for cancer treatment; and TJM2, a GM-CSF monoclonal antibody for rheumatoid arthritis and CAR-T-related therapies. Its product candidates in pre-clinical development comprise TJ210, an antibody targeting myeloid derived suppressor cells in cancers and autoimmune diseases; and TJX7, a novel CXCL13 antibody for autoimmune diseases. The company was founded in 2014 and is headquartered in Shanghai, the People's Republic of China.
For more information, please visit here.